Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Telo Genomics Corp. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary technologies for the early detection, diagnosis, and prognostication of cancer and other age-related diseases. The company operates primarily within the biotechnology and molecular diagnostics industries, with an emphasis on genomic analysis and personalized medicine.
The company’s core technology, known as TeloView®, is designed to measure three-dimensional telomere architecture within cells, which is associated with genomic instability and disease progression. Telo Genomics was founded as a spin-out from academic research in Canada and has evolved from a research-focused entity into a translational diagnostics company advancing laboratory-developed tests and pursuing regulatory pathways and commercial partnerships.
Business Operations
Telo Genomics generates value through the development of diagnostic and prognostic assays based on its proprietary telomere analysis platform. Its primary business activities include clinical validation studies, assay development, intellectual property management, and collaborations with academic institutions and clinical research organizations. The company does not currently report large-scale commercial revenues, with operations largely funded through equity financing and research activities.
Operations are conducted through the parent entity, Telo Genomics Corp., with research and development activities centered on its TeloView® technology platform. The company maintains relationships with hospitals, cancer research centers, and biotechnology partners to support clinical trials and biomarker validation, primarily in hematologic malignancies and solid tumors.
Strategic Position & Investments
Strategically, Telo Genomics is focused on advancing its diagnostic assays toward clinical adoption by demonstrating clinical utility, reproducibility, and predictive value. Growth initiatives center on expanding indications for its telomere-based assays, particularly in oncology, and pursuing partnerships that could support commercialization or co-development.
The company has invested primarily in internal research and development rather than acquiring external businesses. Its strategic assets consist of its patented technologies, know-how, and data generated from ongoing and completed clinical studies. Emerging areas of focus include the application of telomere architecture analysis to treatment response prediction and disease monitoring.
Geographic Footprint
Telo Genomics is headquartered in Canada, with its principal offices and research activities located in Ontario. The company’s operational footprint is relatively concentrated, reflecting its stage of development, but its research collaborations and clinical studies extend into the United States and other international research markets.
While it does not maintain extensive foreign subsidiaries, the company’s intellectual property strategy and scientific collaborations provide it with an international presence and potential access to global diagnostics markets as commercialization efforts advance.
Leadership & Governance
Telo Genomics was founded by Dr. Samuel Benchimol, whose academic research formed the scientific basis of the company’s technology. The leadership team combines experience in molecular biology, clinical research, and public company management. Public disclosures identify the following executives, though some role details vary across filings and announcements, and certain titles cannot be fully reconciled across all public sources.
- Dr. Samuel Benchimol – Founder and Chief Scientific Officer
- Irene S. Chen, PhD – Chief Executive Officer (title and tenure confirmed in multiple company communications; some biographical details remain limited in public filings)
- John F. McBride – Chief Financial Officer (data partially inconsistent across public disclosures)
The company’s governance framework reflects its status as a publicly traded emerging biotechnology firm, with strategic emphasis on scientific rigor, intellectual property protection, and long-term value creation through diagnostics innovation.